Clinical Trial Update: Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR) [Phase 3]

View source ↗

Summary

Phase 3 trial of Dymista nasal spray in children aged 4-11 with seasonal allergic rhinitis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• Dymista Nasal Spray (azelastine hydrochloride and fluticasone propionate nasal spray)

Snippet

Sponsor: Meda Pharmaceuticals | Conditions: Seasonal Allergic Rhinitis | Phase 3 | Status: COMPLETED | Results posted: 2015-06-29